MiMedx
-
Biologics
MiMedx Provides Update on Previously Announced Senior Executive Separations
MARIETTA, Ga., Sept. 20, 2018 /PRNewswire/ — The Board of Directors (the “Board”) of MiMedx Group, Inc. (Nasdaq :MDXG ), a leading developer and…
Read More » -
Biologics
MiMedx Announces Statistically Significant Results In New Multicenter Clinical Study Of Healing Of Diabetic Foot Ulcers Using EpiFix®
MARIETTA, Ga., Aug. 24, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ : MDXG ), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Hospitals
MiMedx Receives Regulatory Approval to Commercialize Product Portfolio in Australia
MARIETTA, Ga., Aug. 9, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced…
Read More » -
Financial
MiMedx Announces Receipt of Nasdaq Letter
MARIETTA, Ga., July 26, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided…
Read More » -
Hospitals
MiMedx Appoints Mark Graves Chief Compliance Officer To Strengthen Corporate Compliance Practices
MARIETTA, Ga., July 18, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced…
Read More » -
Biologics
MiMedx to Highlight Efficacy of Its Allografts in Presentations at SAWC Spring Conference
MARIETTA, Ga., April 23, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today…
Read More » -
Biologics
MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee
MARIETTA, Ga., March 28, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics,…
Read More » -
Biologics
MiMedx Reports Positive Pain And Foot Function Results From Phase 2B Clinical Trial Of AmnioFix® Injectable In The Treatment Of Plantar Fasciitis
MARIETTA, Ga., March 26, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics,…
Read More » -
Financial
MiMedx Postpones Release of its Fourth Quarter and Fiscal Year 2017 Financial Results
MARIETTA, Ga., Feb. 20, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics,…
Read More » -
Biologics
MiMedx Announces First Patients Have Enrolled In The Phase 3 Clinical Trial Of AmnioFix® Injectable In Patients With Recalcitrant Plantar Fasciitis Pain
MARIETTA, Ga., Jan. 16, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Financial
MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016
MARIETTA, Ga., Jan. 7, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Hospitals
MiMedx Agrees To Lawsuit Settlement With Former Employee
MARIETTA, Ga., Dec. 19, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Financial
MiMedx Announces Expectation To Exceed Top End of Fourth Quarter Revenue Guidance Of $88 Million
MARIETTA, Ga., Nov. 30, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More » -
Biologics
MiMedx Provides Update On Its Reimbursement Coverage
MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic…
Read More » -
Biologics
MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document
MARIETTA, Ga., Nov. 17, 2017 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics…
Read More »